HELPING BUSINESSES IN THE POST-GENOMIC ERA
Added: (Tue May 15 2001)
Pressbox (Press Release) -
The mapping of the Human Genome promises to revolutionize the development of new drugs and have an enormous impact on healthcare. It seems likely that the way forward will involve closer collaboration between pharma, biotech, and academia and access to good corporate intelligence will be vital to everyone involved in this field. A sophisticated database from Current Drugs Ltd promises to provide these organizations with the most up-to-date information to make important business decisions. The Investigational Drugs database, IDdb3, is on display this week (14 May) at the EyeforPharma East 2001 conference, in Philadelphia, USA.
IDdb3 is a competitor intelligence and R&D monitoring service that tracks drugs in development from first patent publication to eventual launch or discontinuation.
A major theme of the conference is “business in the post-genomics era” and will bring together representatives from all organizations affected by genomics – financial institutions, academia, industry associations, regulators and large pharmaceutical companies.
Said Jim Jacketti, Current Drugs’ Vice President of US Operations: “It is very appropriate that we are showcasing IDdb3 at this event as the database is proving to be an ideal tool for executives in all these fields looking to develop strategic alliances and identify new business partners. It offers them a fully integrated source of drug discovery intelligence and analysis – covering drugs, companies, patents, scientific meetings and literature.”
IDdb3, widely regarded as the premier source of intelligence on drugs in development, provides a vast array of data including details of over 17,000 developmental drugs, 72,000 therapeutic patents and reports on 14,500 companies/institutes. It is also updated daily, making it one of the fastest pharmaceutical intelligence providers
“IDdb is the most up-to-date source of information on pharmaceutical R&D and is an invaluable competitor intelligence tool for our company. We find the database’s expert evaluations of drugs in development are a particularly useful resource when putting research into context,” commented IDdb3 user Dr Burt Christensen, Executive Vice President, Research, Advanced Medicine Inc, USA.
Further information on IDdb3, including self-running demos, can be found on its web site www.iddb3.com.
Notes to editors
1) EyeforPharma East is at the Pennsylvania Convention Center, Philadelphia, USA from 14 to 16 May.
2) The contact on the Current Drugs stand is Jim Jacketti, VP (US Operations)
Current Drugs Ltd - the world's leading supplier of intelligence services for pharmaceutical R&D. Current Drugs Ltd is headquartered in London, UK and has offices in Philadelphia, USA and Tokyo, Japan. It provides databases, journals and customized software services to the international pharmaceutical industry and is part of the privately owned Current Science Group of companies. http://www.current-drugs.com
Current Drugs Ltd is listed in this year’s Real Business/Dun & Bradstreet Hot 100 companies with “potential star quality”.